Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.6300 (2.35%) ($7.6300 - $7.6300) on Thu. Aug. 25, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7% (three month average) | RSI | 66 | Latest Price | $7.6300(2.35%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.9% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XLK(97%) XLC(92%) SPY(91%) XBI(89%) PAVE(86%) | Factors Impacting TGTX price | TGTX will decline at least -3.5% in a week (0% probabilities). UUP(-59%) USO(-19%) XOP(9%) TBT(-23%) TIP(7%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.5% (StdDev 7%) | Hourly BBV | 0.9 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.11(7.31%) | 10 Day Moving Average | $7.45(2.42%) | 20 Day Moving Average | $7.09(7.62%) | To recent high | -9.4% | To recent low | 104.3% | Market Cap | $966m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |